title: Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions.
abstract: It was hypothesized that under induced lipid malabsorption/maldigestion conditions, an enriched sn-1(3)-monoacylglycerol (MAG) oil may be a better carrier for n-3 long-chain PUFAs (LC-PUFAs) compared with triacylglycerol (TAG) from fish oil. This monocentric double blinded clinical trial examined the accretion of EPA (500 mg/day) and DHA (300 mg/day) when consumed as TAG or MAG, into the erythrocytes, plasma, and chylomicrons of 45 obese (BMI ≥30 kg/m2and ≤40 kg/m2) volunteers who were and were not administered Orlistat, an inhibitor of pancreatic lipases. Intake of MAG-enriched oil resulted in higher accretion of LC-PUFAs than with TAG, the concentrations of EPA and DHA in erythrocytes being, respectively, 72 and 24% higher at 21 days (P < 0.001). In addition, MAG increased the plasma concentration of EPA by 56% (P < 0.001) as compared with TAG. In chylomicrons, MAG intake yielded higher levels of EPA with the area under the curve (0-10 h) of EPA being 55% greater (P = 0.012). In conclusion, in obese human subjects with Orlistat-induced lipid maldigestion/malabsorption conditions, LC-PUFA MAG oil increased LC-PUFA levels in erythrocytes, plasma, and chylomicrons to a greater extent than TAG. These results indicate that MAG oil might require minimal enzymatic digestion prior to intestinal uptake and transfer across the epithelial barrier.
authors.affiliation: Nestlé Research Center, 1000 Lausanne, Switzerland. Electronic address: cristina.cruz-hernandez@rdls.nestle.com.
authors.forename: Cristina
authors.initials: C
authors.lastname: Cruz-Hernandez
authors.affiliation: Nestlé Research Center, 1000 Lausanne, Switzerland.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Destaillats
authors.affiliation: Nestlé Research Center, 1000 Lausanne, Switzerland.
authors.forename: Sagar K
authors.initials: SK
authors.lastname: Thakkar
authors.affiliation: Nestlé Research Center, 1000 Lausanne, Switzerland.
authors.forename: Laurence
authors.initials: L
authors.lastname: Goulet
authors.affiliation: Nestlé Research Center, 1000 Lausanne, Switzerland.
authors.forename: Emma
authors.initials: E
authors.lastname: Wynn
authors.affiliation: Nestlé Research Center, 1000 Lausanne, Switzerland.
authors.forename: Dominik
authors.initials: D
authors.lastname: Grathwohl
authors.affiliation: Nestlé Research Center, 1000 Lausanne, Switzerland.
authors.forename: Claudia
authors.initials: C
authors.lastname: Roessle
authors.affiliation: Department of Physiology, Faculty of Biology and Medicine, 1005 Lausanne, Switzerland.
authors.forename: Sara
authors.initials: S
authors.lastname: de Giorgi
authors.affiliation: Department of Physiology, Faculty of Biology and Medicine, 1005 Lausanne, Switzerland.
authors.forename: Luc
authors.initials: L
authors.lastname: Tappy
authors.affiliation: Nestlé Research Center, 1000 Lausanne, Switzerland.
authors.forename: Francesca
authors.initials: F
authors.lastname: Giuffrida
authors.affiliation: University of Lausanne, 1005 Lausanne, Switzerland.
authors.forename: Vittorio
authors.initials: V
authors.lastname: Giusti
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use; D002462:Cell Membrane / Q000378:metabolism; D002914:Chylomicrons; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005395:Fish Oils / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D052439:Lipid Metabolism Disorders / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D050178:Monoglycerides / Q000008:administration & dosage*; D009765:Obesity / Q000097:blood / Q000188:drug therapy; D000077403:Orlistat
chemical_list: D019440:Anti-Obesity Agents; D002914:Chylomicrons; D005395:Fish Oils; D007783:Lactones; D050178:Monoglycerides; D004281:Docosahexaenoic Acids; D000077403:Orlistat; D015118:Eicosapentaenoic Acid
keywords: Orlistat; clinical trials; diet effects/lipid metabolism; digestion; docosahexaenoic acid; eicosapentaenoic acid; fatty acid/metabolism; lipase; lipid absorption; obese; polyunsaturated fatty acid